Clinical trial
A Study to Evaluate the Effectiveness of Voriconazole + Micafungin Versus…
NCT00423163 · Astellas Pharma Inc, Industry · Withdrawn
Key facts
| NCT number | NCT00423163 |
|---|---|
| Title | A Study to Evaluate the Effectiveness of Voriconazole + Micafungin Versus Voriconazole Alone for Invasive Aspergillosis |
| Official title | A Double-Blind, Randomized Controlled Trial of Voriconazole (VFEND®) Plus Micafungin (MYCAMINE™) Versus Voriconazole Plus Placebo in the Treatment of Patients With Proven or Probable Invasive Aspergillosis |
| Lead sponsor | Astellas Pharma Inc, Industry |
| Status | Withdrawn |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Aspergillosis/Blood, Aspergillosis/Invasive |
| Intervention type | Drug |
| Interventions | micafungin, voriconazole |
| Enrollment | 0 |
| Start date | Feb 1, 2007 |
| First posted | Jan 18, 2007 |
| Last update posted | Sep 2, 2015 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: